Skip to main content
Clinical Trials/NCT03999411
NCT03999411
Completed
Phase 4

A Novel Smartphone-based Intervention to Support Smoking Cessation and Adherence to Antiretroviral Therapy Among People Living With HIV: A Pilot Randomized Clinical Trial

University of Miami1 site in 1 country39 target enrollmentSeptember 9, 2019

Overview

Phase
Phase 4
Intervention
Nicoderm C-Q Transdermal Product
Conditions
Smoking
Sponsor
University of Miami
Enrollment
39
Locations
1
Primary Endpoint
Number of Participants With Smoking Cessation
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to learn if a mindfulness-based smoking cessation smartphone app can help people quit smoking and stay on antiretroviral therapies.

Detailed Description

The current study aims to test the feasibility of a three-arm randomized clinical trial testing the combined mindfulness training + Emocha apps intervention versus the mindfulness training app only with brief advice to improve ART adherence and usual care (UC; brief advice to quit and improve ART adherence). Our primary hypothesis is that the combination of mindfulness training + Emocha apps would be superior to the mindfulness training app with brief advice to improve ART adherence, and these two interventions would be superior to the UC in terms of the feasibility, acceptability, and potential efficacy (3-month smoking cessation; improvement in adherence to ART).

Registry
clinicaltrials.gov
Start Date
September 9, 2019
End Date
October 14, 2020
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Taghrid Asfar

Research Assistant Professor

University of Miami

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years old
  • Diagnosed with HIV
  • Have been prescribed ART medication in the prior 6 months
  • Have smoked ≥ 5 cigarettes/day in the past year
  • Be interested in making a quit attempt in the next 30 days
  • Own a smartphone (apple/android)and plan to keep it active for the following 3 months
  • Read/speak English
  • Be able to provide consent
  • Have no plans to move in the next 3 months
  • Not pregnant or planning to be pregnant in the following 3 months

Exclusion Criteria

  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
  • Have contraindication to NRT (past month myocardial infarction, history of serious arrhythmias/or unstable angina pectoris, dermatological disorder)
  • Currently being treated for a psychiatric condition
  • Currently being treated for smoking cessation, alcoholism, or illicit drug use

Arms & Interventions

Usual Care

Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.

Intervention: Nicoderm C-Q Transdermal Product

Usual Care

Participants will receive brief advice to adhere to ART brief advice to quit smoking, 6-week supplies of nicotine-replacement therapy (NRT), and self-help materials to quit smoking and adhere to ART.

Intervention: Adherence to Antiretroviral Therapy Counseling

Smoking cessation only intervention

Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the "Crave-to-Quit" app, and two brief follow-up phone calls.

Intervention: Nicoderm C-Q Transdermal Product

Smoking cessation only intervention

Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the "Crave-to-Quit" app, and two brief follow-up phone calls.

Intervention: Adherence to Antiretroviral Therapy Counseling

Smoking cessation only intervention

Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the "Crave-to-Quit" app, and two brief follow-up phone calls.

Intervention: Behavioral Smoking Cessation Counseling

Smoking cessation only intervention

Participants in this group will receive the usual care (UC) for adherence to ART, one in-person orientation sessions, 6-week supplies of NRT the "Crave-to-Quit" app, and two brief follow-up phone calls.

Intervention: "Crave-to-Quit" app

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Intervention: Nicoderm C-Q Transdermal Product

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Intervention: Adherence to Antiretroviral Therapy Counseling

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Intervention: Behavioral Smoking Cessation Counseling

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Intervention: "Crave-to-Quit" app

Combined smoking cessation and HIV intervention

Participants in this group will receive everything given in the Smoking Cessation Only arm and will also use the emocha app and will receive a tutorial explaining the app content and features. The study team will explain to participants that the app will help them in tracking dose-by-dose medication adherence by recording a video for themselves taking their medication.

Intervention: vDOT "emocha" app

Outcomes

Primary Outcomes

Number of Participants With Smoking Cessation

Time Frame: Up to 3 months

Participants who self-report seven days of non-smoking.

Number of Participants With ≥ 95% Adherence to ART Medication Based on the Visual Analogue Scale

Time Frame: 3 months

Number of participants with ≥ 95% Adherence to ART Medication Based on the Visual Analogue Scale ranging from 0 to 100%. The ART medication visual analogue scale is an instrument for patients to rate their dose taken percentages (≥ 95% of doses taken will be regarded as good adherence). Higher score (0 to 100%) indicates higher adherence to ART.

Usability of Intervention Questionnaire Score

Time Frame: 3 months

The usability of the Craving-to Quit and Emocha apps will be assessed via a questionnaire with scores ranging from 0-10 with the higher score indicating increased comfortability with using the app.

Acceptability of Intervention Questionnaire Scores

Time Frame: 3 months

The acceptability is be assessed by 3 items "How satisfied were you with the intervention?", "How likely are you to recommend this intervention to a friend?" and "How useful was the intervention?" Each question is scored from 0-10 with the higher score indicating increased acceptability.

Number of Participants Reporting Engagement With the Intervention

Time Frame: Up to 3 months

Participant engagement is evaluated via self-reported use of the Craving-to-Quit and Emocha apps. Participants will complete a questionnaire indicating how often they used the apps. The response categories include: Everyday, often, some days, not often, not at all. We report the number of participants in each category or combination of categories.

Feasibility of Delivery

Time Frame: At screening through study completion (up to 3 months)

The feasibility of delivery will be assessed via evaluating the: 1. eligible, defined as number of participants eligible out of total screened 2. recruitment rate, defined as number of participants enrolled out of total screened 3. total completing all study activities, defined as the number of participants completing all activities out of total enrolled

Secondary Outcomes

  • Number of Cigarettes Smoked Per Day(At baseline and at 3 months)
  • Number of Participants With Reported Relapse(Up to 3 months)

Study Sites (1)

Loading locations...

Similar Trials